Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Patient Preference and Adherence

Volumn 3, Issue , 2008, Pages 25-30

  Höer, Ariane ^a   Seidlitz, Cornelia ^a   Gothe, Holger ^a   Schiffhorst, Guido ^a   Olson, Melvin ^b   Hadji, Peyman ^b   Häussler, Bertram ^a  

^a IGES Institut Gmbh   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Compliance; Fracture risk; Oral bisphosphonates; Persistence

Indexed keywords

EID: 70349397361     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4673     Document Type: Article

References (11)

1. List of National and Regional Osteoporosis Guidelines. International Osteoporosis Foundation. Available from: http://www.iofbonehealth. org/health-professionals/national-regional-guidelines/evidence-basedguidelines. html (Accessed December 04, 2007).
2. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002;166:1426-1430.
3. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-287.
4. Penning-van Beest FJA, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511-517.
5. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-1008.
6. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
7. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.
8. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645-1652.
9. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811-818.
10. DVO (Dachverband der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften). Prophylaxe, Diagnostik und Therapie der Osteoporose. 2006.
11. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9(22):1-160.